Harnessing the bioresponsive adhesion of immuno-bioglue for enhanced local immune checkpoint blockade therapy. (December 2020)

• Record Type: Journal Article
• Authors: Joo, Kye Il; Jeong, Yeonsu; Hwang, Sung-Min; Shin, Mincheol; Lee, Jaeyun; Sharma, Garima; Lee, Haena; Im, Sin-Hyeog; Cha, Hyung Joon
• Is Part Of: Biomaterials. Volume 263(2020)
• Publication Date: 2020-12
• Subjects: Immune checkpoint blockade -- Mussel adhesive protein -- Localized immunotherapy -- Combination cancer immunotherapy -- Anti-PD-L1; Biomedical materials -- Periodicals; Biocompatible Materials -- Periodicals; Biomatériaux -- Périodiques; 610.28
• DOI: 10.1016/j.biomaterials.2020.120380
• Languages: English
• ISSNs: 0142-9612

Abstract

Abstract: Despite the great promise of immune checkpoint blockade (ICB) therapy for cancer treatment, the currently available options for ICB treatment pose major clinical challenges, including the risk of severe systemic autoimmune responses. Here, we developed a novel localized delivery platform, immuno-bioglue (imuGlue), which is inspired by the intrinsic underwater adhesion properties of marine mussels and can allow the optimal retention of anti-PD-L1 drugs at tumor sites and the on-demand release of drugs in response to the tumor microenvironment. Using a triple-negative breast cancer and melanoma models, we found that imuGlue could significantly enhance anti-tumor efficacy by eliciting a robust T cell-mediated immune response while reducing systemic toxicity by preventing the rapid diffusion of anti-PD-L1 drugs into the systemic circulation and other tissues. It was also demonstrated that imuGlue could be successfully utilized for combination therapy with other immunomodulatory drugs to enhance the anti-tumor efficacy of ICB-based immunotherapy, demonstrating its versatility as a new treatment option for cancer immunotherapy. Graphical abstract: Immuno-Bioglue (imuGlue), inspired by the intrinsic underwater adhesion properties of marine mussels, is a stimuli-responsive localized delivery platform for immune checkpoint inhibitors that can allow the prolonged retention of checkpoint inhibitors in tumor sites and the on-demand release of the inhibitors in response to the tumor microenvironment. Image 1